Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.

Investigating macro marine litter and beach cleanliness along Southern Vietnam beaches.

Plastic contamination is a major issue for marine ecosystems, with macro-litter posing a growing threat globally. This study assesses macro-marine litter on Vung Tau beaches, Southern Vietnam, providing baseline data for marine litter pollution and identifying critical action plans for plastic control. Survey results showed litter density ranging from 0.

Digital analysis of the relationship between maximum bite force and 3-dimensional arrangement of mandibular first molars.

Background: Bite force is one of the important factors that determine the chewing efficiency of molars. This study aimed to investigate the relationship of the maximum bite force (MBF) to the 3-dimensional (3D) arrangement of the first mandibular molars in Angle's class I healthy adults using a digital protocol.

Material And Methods: Subjects were 33 adults (16 males and 17 females) aged 18-25, with Angle's class I occlusions and healthy dentitions.

Risk of cardiovascular disease following degarelix versus gonadotropin-releasing hormone agonists in patients with prostate cancer: a systematic review and meta-analysis.

Background: Prostate cancer treatment involves hormonal therapies that may carry cardiovascular risks, particularly for long-term use. Gonadotropin-releasing hormone (GnRH) antagonists, such as degarelix, may offer advantages over agonists, but comprehensive comparative cardiovascular outcomes are not well established. This study aimed to systematically review and analyze the cardiovascular safety profiles of degarelix compared to those of traditional GnRH agonists, providing critical insights for optimizing treatment strategies.

Optimized synthesis of biphasic calcium phosphate: enhancing bone regeneration with a tailored β-tricalcium phosphate/hydroxyapatite ratio.

Biphasic calcium phosphate (BCP) is a bioceramic widely used in hard tissue engineering for bone replacement. BCP consists of β-tricalcium phosphate (β-TCP) - a highly soluble and resorbable phase - and hydroxyapatite (HA) - a highly stable phase, creating a balance between solubility and resorption, optimally supporting cell interactions and tissue growth. The β-TCP/HA ratio significantly affects the resorption, solubility, and cellular response, with a higher β-TCP ratio increasing resorption due to its solubility.